Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hansizhuang + nab-paclitaxel in advanced cervical cancer
NCT04150575Phase 2Unknown
- Sponsor
- Henlius
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in Cervical Cancer (CC), sponsored by Henlius. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04150575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150575.